This report aims to provide a comprehensive presentation of the global market for Generic and Biosimilar Pharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic and Biosimilar Pharmaceuticals. This report contains market size and forecasts of Generic and Biosimilar Pharmaceuticals in global, including the following market information:
Global Generic and Biosimilar Pharmaceuticals Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Generic and Biosimilar Pharmaceuticals market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Monoclonal Antibodies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Generic and Biosimilar Pharmaceuticals include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Generic and Biosimilar Pharmaceuticals companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Generic and Biosimilar Pharmaceuticals Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Generic and Biosimilar Pharmaceuticals Market Segment Percentages, by Type, 2022 (%)
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Global Generic and Biosimilar Pharmaceuticals Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Generic and Biosimilar Pharmaceuticals Market Segment Percentages, by Application, 2022 (%)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Global Generic and Biosimilar Pharmaceuticals Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Generic and Biosimilar Pharmaceuticals Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Generic and Biosimilar Pharmaceuticals revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Generic and Biosimilar Pharmaceuticals revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Outline of Major Chapters:
Chapter 1: Introduces the definition of Generic and Biosimilar Pharmaceuticals, market overview.
Chapter 2: Global Generic and Biosimilar Pharmaceuticals market size in revenue.
Chapter 3: Detailed analysis of Generic and Biosimilar Pharmaceuticals company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Generic and Biosimilar Pharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Generic and Biosimilar Pharmaceuticals Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Generic and Biosimilar Pharmaceuticals Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Generic and Biosimilar Pharmaceuticals Overall Market Size
2.1 Global Generic and Biosimilar Pharmaceuticals Market Size: 2022 VS 2029
2.2 Global Generic and Biosimilar Pharmaceuticals Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Generic and Biosimilar Pharmaceuticals Players in Global Market
3.2 Top Global Generic and Biosimilar Pharmaceuticals Companies Ranked by Revenue
3.3 Global Generic and Biosimilar Pharmaceuticals Revenue by Companies
3.4 Top 3 and Top 5 Generic and Biosimilar Pharmaceuticals Companies in Global Market, by Revenue in 2022
3.5 Global Companies Generic and Biosimilar Pharmaceuticals Product Type
3.6 Tier 1, Tier 2 and Tier 3 Generic and Biosimilar Pharmaceuticals Players in Global Market
3.6.1 List of Global Tier 1 Generic and Biosimilar Pharmaceuticals Companies
3.6.2 List of Global Tier 2 and Tier 3 Generic and Biosimilar Pharmaceuticals Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Generic and Biosimilar Pharmaceuticals Market Size Markets, 2022 & 2029
4.1.2 Monoclonal Antibodies
4.1.3 Interferon
4.1.4 Erythropoietin
4.1.5 Insulin
4.1.6 Vaccines
4.1.7 Other
4.2 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue & Forecasts
4.2.1 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue, 2018-2023
4.2.2 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue, 2024-2029
4.2.3 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Generic and Biosimilar Pharmaceuticals Market Size, 2022 & 2029
5.1.2 Tumor
5.1.3 Diabetes
5.1.4 Cardiovascular
5.1.5 Hemophilia
5.1.6 Other
5.2 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue & Forecasts
5.2.1 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue, 2018-2023
5.2.2 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue, 2024-2029
5.2.3 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Generic and Biosimilar Pharmaceuticals Market Size, 2022 & 2029
6.2 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue & Forecasts
6.2.1 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue, 2018-2023
6.2.2 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue, 2024-2029
6.2.3 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Generic and Biosimilar Pharmaceuticals Revenue, 2018-2029
6.3.2 US Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.3.3 Canada Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.3.4 Mexico Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue, 2018-2029
6.4.2 Germany Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4.3 France Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4.4 U.K. Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4.5 Italy Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4.6 Russia Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4.7 Nordic Countries Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.4.8 Benelux Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue, 2018-2029
6.5.2 China Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.5.3 Japan Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.5.4 South Korea Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.5.5 Southeast Asia Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.5.6 India Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Generic and Biosimilar Pharmaceuticals Revenue, 2018-2029
6.6.2 Brazil Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.6.3 Argentina Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue, 2018-2029
6.7.2 Turkey Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.7.3 Israel Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.7.4 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
6.7.5 UAE Generic and Biosimilar Pharmaceuticals Market Size, 2018-2029
7 Generic and Biosimilar Pharmaceuticals Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.2.5 Amgen Key News & Latest Developments
7.3 AbbVie
7.3.1 AbbVie Company Summary
7.3.2 AbbVie Business Overview
7.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.3.5 AbbVie Key News & Latest Developments
7.4 Sanofi-Aventis
7.4.1 Sanofi-Aventis Company Summary
7.4.2 Sanofi-Aventis Business Overview
7.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.4.5 Sanofi-Aventis Key News & Latest Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Company Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.5.5 Johnson & Johnson Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Company Summary
7.7.2 Novo Nordisk Business Overview
7.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.7.5 Novo Nordisk Key News & Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Company Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.8.5 Eli Lilly Key News & Latest Developments
7.9 Novartis
7.9.1 Novartis Company Summary
7.9.2 Novartis Business Overview
7.9.3 Novartis Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.9.5 Novartis Key News & Latest Developments
7.10 Merck
7.10.1 Merck Company Summary
7.10.2 Merck Business Overview
7.10.3 Merck Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.10.5 Merck Key News & Latest Developments
7.11 3sbio
7.11.1 3sbio Company Summary
7.11.2 3sbio Business Overview
7.11.3 3sbio Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.11.5 3sbio Key News & Latest Developments
7.12 Changchun High Tech
7.12.1 Changchun High Tech Company Summary
7.12.2 Changchun High Tech Business Overview
7.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.12.5 Changchun High Tech Key News & Latest Developments
7.13 CP Guojian
7.13.1 CP Guojian Company Summary
7.13.2 CP Guojian Business Overview
7.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.13.5 CP Guojian Key News & Latest Developments
7.14 Biotech
7.14.1 Biotech Company Summary
7.14.2 Biotech Business Overview
7.14.3 Biotech Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.14.5 Biotech Key News & Latest Developments
7.15 Gelgen
7.15.1 Gelgen Company Summary
7.15.2 Gelgen Business Overview
7.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.15.5 Gelgen Key News & Latest Developments
7.16 Innovent
7.16.1 Innovent Company Summary
7.16.2 Innovent Business Overview
7.16.3 Innovent Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.16.5 Innovent Key News & Latest Developments
7.17 Dong Bao
7.17.1 Dong Bao Company Summary
7.17.2 Dong Bao Business Overview
7.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.17.5 Dong Bao Key News & Latest Developments
7.18 Ganlee
7.18.1 Ganlee Company Summary
7.18.2 Ganlee Business Overview
7.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Major Product Offerings
7.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue in Global Market (2018-2023)
7.18.5 Ganlee Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Generic and Biosimilar Pharmaceuticals Market Opportunities & Trends in Global Market
Table 2. Generic and Biosimilar Pharmaceuticals Market Drivers in Global Market
Table 3. Generic and Biosimilar Pharmaceuticals Market Restraints in Global Market
Table 4. Key Players of Generic and Biosimilar Pharmaceuticals in Global Market
Table 5. Top Generic and Biosimilar Pharmaceuticals Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Generic and Biosimilar Pharmaceuticals Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Companies, 2018-2023
Table 8. Global Companies Generic and Biosimilar Pharmaceuticals Product Type
Table 9. List of Global Tier 1 Generic and Biosimilar Pharmaceuticals Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Generic and Biosimilar Pharmaceuticals Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2024-2029
Table 30. Roche Company Summary
Table 31. Roche Generic and Biosimilar Pharmaceuticals Product Offerings
Table 32. Roche Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen Generic and Biosimilar Pharmaceuticals Product Offerings
Table 36. Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 37. Amgen Key News & Latest Developments
Table 38. AbbVie Company Summary
Table 39. AbbVie Generic and Biosimilar Pharmaceuticals Product Offerings
Table 40. AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 41. AbbVie Key News & Latest Developments
Table 42. Sanofi-Aventis Company Summary
Table 43. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Offerings
Table 44. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 45. Sanofi-Aventis Key News & Latest Developments
Table 46. Johnson & Johnson Company Summary
Table 47. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Offerings
Table 48. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 49. Johnson & Johnson Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Generic and Biosimilar Pharmaceuticals Product Offerings
Table 52. Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Novo Nordisk Company Summary
Table 55. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Offerings
Table 56. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 57. Novo Nordisk Key News & Latest Developments
Table 58. Eli Lilly Company Summary
Table 59. Eli Lilly Generic and Biosimilar Pharmaceuticals Product Offerings
Table 60. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 61. Eli Lilly Key News & Latest Developments
Table 62. Novartis Company Summary
Table 63. Novartis Generic and Biosimilar Pharmaceuticals Product Offerings
Table 64. Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 65. Novartis Key News & Latest Developments
Table 66. Merck Company Summary
Table 67. Merck Generic and Biosimilar Pharmaceuticals Product Offerings
Table 68. Merck Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 69. Merck Key News & Latest Developments
Table 70. 3sbio Company Summary
Table 71. 3sbio Generic and Biosimilar Pharmaceuticals Product Offerings
Table 72. 3sbio Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 73. 3sbio Key News & Latest Developments
Table 74. Changchun High Tech Company Summary
Table 75. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Offerings
Table 76. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 77. Changchun High Tech Key News & Latest Developments
Table 78. CP Guojian Company Summary
Table 79. CP Guojian Generic and Biosimilar Pharmaceuticals Product Offerings
Table 80. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 81. CP Guojian Key News & Latest Developments
Table 82. Biotech Company Summary
Table 83. Biotech Generic and Biosimilar Pharmaceuticals Product Offerings
Table 84. Biotech Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 85. Biotech Key News & Latest Developments
Table 86. Gelgen Company Summary
Table 87. Gelgen Generic and Biosimilar Pharmaceuticals Product Offerings
Table 88. Gelgen Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 89. Gelgen Key News & Latest Developments
Table 90. Innovent Company Summary
Table 91. Innovent Generic and Biosimilar Pharmaceuticals Product Offerings
Table 92. Innovent Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 93. Innovent Key News & Latest Developments
Table 94. Dong Bao Company Summary
Table 95. Dong Bao Generic and Biosimilar Pharmaceuticals Product Offerings
Table 96. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 97. Dong Bao Key News & Latest Developments
Table 98. Ganlee Company Summary
Table 99. Ganlee Generic and Biosimilar Pharmaceuticals Product Offerings
Table 100. Ganlee Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn) & (2018-2023)
Table 101. Ganlee Key News & Latest Developments
List of Figures
Figure 1. Generic and Biosimilar Pharmaceuticals Segment by Type in 2022
Figure 2. Generic and Biosimilar Pharmaceuticals Segment by Application in 2022
Figure 3. Global Generic and Biosimilar Pharmaceuticals Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Generic and Biosimilar Pharmaceuticals Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Generic and Biosimilar Pharmaceuticals Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Generic and Biosimilar Pharmaceuticals Revenue in 2022
Figure 8. By Type - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 9. By Application - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 10. By Type - Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 12. By Application - Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 14. By Region - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 15. By Country - North America Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 16. US Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 20. Germany Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 21. France Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 28. China Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 32. India Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 34. Brazil Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2018-2029
Figure 37. Turkey Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2018-2029
Figure 41. Roche Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Amgen Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AbbVie Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Pfizer Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Novartis Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Merck Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. 3sbio Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Biotech Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Gelgen Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Innovent Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Ganlee Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
